

32-1349: IGFBP3 Recombinant Protein

Alternative Name : Growth-hormone-dependant binding protein,IBP3,BP-53,IGFBP-3.

Description

Source : Escherichia Coli. IGFBP3 Human Recombinant produced in E.Coli is a homodimeric, non-glycosylated, polypeptide chain containing 2x264 amino acids and having a molecular mass of 28806 Dalton. IGFBP-3 is purified by proprietary chromatographic techniques. IGFBP3 is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Product Info

Amount :	25 µg
Purification :	Greater than 97.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.
Content :	Lyophilized from a 0.2µm filtered concentrated (0.5mg/ml) solution in PBS, pH 7.4.
Storage condition :	Lyophilized IBP3 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IGF-BP 3 should be stored at 4°C between 2-7 days and for future use below -18°C.For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.
Amino Acid :	GASSGGLGPV VRCEPCDARA LAQCAPPVAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG EVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTDT QNFSSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDDKGFYK KQQRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK.

Application Note

It is recommended to reconstitute the lyophilized Insulin-Like Growth Factor Binding Protein-3 in sterile 20mM AcOH (acetic Acid) not less than 100µg/ml, which can then be further diluted to other aqueous solutions. The ED50, calculated by its ability to inhibit IGF-II induced proliferation of MCF-7 is < 0.2 µg/ml in the presence of 15 ng/ml of Human IGF-II, corresponding to a specific activity of 5,000,000units/mg.

